Interferons and Other Biological Response Modifiers in the Treatment of Kaposi�s Sarcoma1
Susan E. Krown(Memorial Sloan Kettering Cancer Center), Herbert F. Oettgen, Mathilde Krim, Bijan Safai(Metropolitan Hospital Center), Patricia L. Myskowski(Memorial Sloan Kettering Cancer Center), Benjamín Koziner(Leukemia and Lymphoma Society), Susanna Cunningham–Rundles(NewYork–Presbyterian Hospital), Francisco X. Real(Universitat Pompeu Fabra)
Cited by 7
Related Papers
Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS
|Science|1984|3.6k
Kaposi sarcoma
|Nature Reviews Disease Primers|2019|707
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|654
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses
|The Lancet|2005|631
GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody.
|The Journal of Experimental Medicine|1982|577